NEW YORK (GenomeWeb News) – Danish proteomics firm Proxeon has raised DKK14 million ($2.4 million) in a round of private financing from venture capital investors.

The firm did not say in its statement who the venture capital investors are for this round, but according to the firm's website investment firms Vecata and Inventure Capital are among its investors.

Proxeon said that the investment is expected to be sufficient to help the firm reach positive cash flow. It also noted that it expects to record full-year 2008 revenue growth of more than 60 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: The sea anemone is sequenced, a team describes a CRISPR/Cas9-based approach to label specific sites in the genome, and more. 

In a short video, CNN introduces viewers to a fecal transplant poop donor and explains how the treatments are made.

Researchers are testing the use of transgenically altered diamondback moths as an alternative to pesticides in controlling the bugs.

Two recent papers published in Science and Nature Medicine describe work that may result in a universal vaccine for the flu.